TG Therapeutics (TGTX) closed at $54.17 on Oct 23, 2026, up 1.9% on the day. The stock is down 5.8% over the past month, down 2.8% over three months, up 81.7% year to date and up 56.6% over the past year. It trades 8.7% below its 52-week high of $59.30 and 102.4% above its 52-week low of $26.76. The close sits below its 50-day moving average ($54.58) and above its 200-day moving average ($43.09).
NextPick tracks TGTX in its Biotech basket alongside VRTX, REGN, MRNA, BIIB and ALNY. As of Oct 23, 2026, the basket's money-flow score is -10 (neutral), and the basket is up 3.5% over five sessions. Over the past month TGTX ranks 11th of 17 basket members by price change.
Yes — the Oct 23, 2026 close of $54.17 is 25.7% above the 200-day average of $43.09.
TGTX closed 8.7% below its 52-week high of $59.30.
NextPick groups TGTX with VRTX, REGN, MRNA, BIIB and ALNY in its Biotech basket.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
